Shopping Cart
Remove All
Your shopping cart is currently empty
Bivatuzumab (BIWA 4) is a humanized monoclonal antibody against CD44v6.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $213 | - | In Stock | |
| 5 mg | $645 | - | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,530 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
| Description | Bivatuzumab (BIWA 4) is a humanized monoclonal antibody against CD44v6. |
| In vitro | At a concentration of 10 μg/mL, Bivatuzumab stains CD44v6 in STS cells [1]. |
| Synonyms | BIWA 4 |
| Reactivity | Human |
| Verified Activity | Immobilized Human CD44 Protein (Fc) at 2 μg/mL (30 μL/well) can bind Bivatuzumab. The EC50 is 18.24 ng/mL. ![]() |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD44v6 |
| Molecular Weight | 143.22 kDa |
| Cas No. | 214559-60-1 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.